Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept
View HTML
Toggle Summary Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting
– Phase 3 MEDALIST trial results to be presented in Plenary Scientific Session – – Phase 3 BELIEVE trial results to be shared in oral presentation – – Acceleron to hold conference call and webcast live from ASH, December 3 , at 9:00 a.m. EST – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary Acceleron Reports Third Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes (MDS) and beta-thalassemia, respectively, are expected to be presented at the 60 th American Society of Hematology (ASH) Annual Meeting – – COMMANDS Phase 3 trial in patients with lower-risk MDS who are treatment naïve has
View HTML
Toggle Summary Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.m. EDT to discuss its third quarter 2018 operating and financial results.
View HTML
Toggle Summary Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City
– Live presentation and webcast to be held on November 16 th  at 9:00 a.m. EST – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 16, 2018-- Acceleron Pharma Inc.  (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare
View HTML
Toggle Summary Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of
View HTML
Toggle Summary Acceleron to Participate in Three Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming
View HTML
Toggle Summary Acceleron Reports Second Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints – – ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway – – PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension –
View HTML
Toggle Summary Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results.
View HTML
Toggle Summary Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society
- Mean total muscle volume increases of more than 12% seen in the tibialis anterior – - Company plans to initiate Part 2 of the CMT Phase 2 trial in the third quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 23, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
View HTML